SER Serina Therapeutics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1708599 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY132.1%
TTM net income YoY-72.2%
TTM EPS YoY-26.5%
Revenue 3-yr CAGR56.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-18,478.5%
Net margin-14,755.4%
FCF margin-13,856.9%
EBITDA margin-18,439.2%
Returns
ROE-6,351.7%
ROA-280.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets100.5%
Debt / equity—
Current ratio1.71x
Interest coverage-112.78x
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-17.9%
Payout ratio—
Capex / revenue45.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $125,000 | $0 | — | $0 | $0 | $130,000 | $0 | -$14,000 |
| R&D expense | $4.63M | $3.82M | $3.20M | $3.40M | $3.65M | $3.15M | $2.95M | $2.37M |
| SG&A expense | $3.36M | $2.97M | $3.08M | $2.81M | $2.74M | $2.54M | $2.91M | $3.17M |
| Operating income | -$7.86M | -$6.78M | — | -$6.21M | -$6.39M | -$5.57M | -$5.86M | -$5.55M |
| Interest expense | $204,000 | $203,000 | $189,000 | $198,000 | $6,000 | $9,000 | $0 | $17,000 |
| Pretax income | — | — | -$6.89M | — | — | — | -$4.82M | — |
| Income tax | — | — | $7,000 | — | — | — | $0 | — |
| Net income | -$7.91M | -$6.36M | -$6.90M | -$3.34M | -$4.58M | -$6.45M | -$4.81M | -$2.74M |
| EBITDA | -$7.84M | -$6.75M | — | -$6.16M | -$6.39M | -$5.57M | -$5.86M | -$5.59M |
| EPS (basic) | -0.31 | -0.55 | -0.58 | — | -0.45 | -0.66 | -0.49 | — |
| EPS (diluted) | -0.31 | -0.55 | -0.58 | — | -0.45 | -0.66 | -0.49 | — |
| Weighted avg. shares (diluted) | 25.41M | 16.39M | 12.05M | — | 10.34M | 10.00M | 9.76M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $19.40M | $23.02M | $24.53M | $3.06M | $8.62M | $6.04M | $4.27M | $3.67M |
| Current assets | $20.93M | $25.03M | $26.47M | $6.08M | $11.50M | $7.99M | $5.75M | $5.68M |
| PP&E, net | $466,000 | $482,000 | $472,000 | $465,000 | $580,000 | $588,000 | $484,000 | $501,000 |
| Total assets | $21.87M | $25.81M | $27.30M | $6.95M | $12.41M | $8.94M | $6.73M | $6.72M |
| Current liabilities | $4.53M | $3.76M | $6.34M | $3.56M | $8.79M | $3.56M | $2.35M | $2.37M |
| Total liabilities | $7.95M | $7.08M | $9.67M | $6.99M | $10.82M | $7.29M | $5.17M | $6.22M |
| Shareholders' equity | $13.92M | $18.73M | $17.63M | -$37,000 | $1.76M | $1.80M | $1.70M | $641,000 |
| Shares outstanding | 26.41M | 25.40M | 14.90M | 10.77M | 10.54M | 10.14M | 9.93M | 9.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.50M | -$6.68M | -$4.57M | -$6.03M | -$3.85M | -$3.75M | -$4.32M | -$4.59M |
| Capital expenditure | $3,000 | $28,000 | $25,000 | $0 | $13,000 | $46,000 | $0 | $5,000 |
| Free cash flow | -$5.50M | -$6.71M | -$4.59M | -$6.03M | -$3.86M | -$3.80M | -$4.32M | -$4.59M |
| Investing cash flow | -$3,000 | -$28,000 | -$25,000 | $0 | -$13,000 | -$46,000 | $0 | -$5,000 |
| Financing cash flow | $1.88M | $5.20M | $26.06M | $481,000 | $6.44M | $5.57M | $4.92M | $5.03M |
| Depreciation & amortization | $19,000 | $36,000 | $0 | $51,000 | $0 | $0 | $0 | -$38,000 |
| Stock-based compensation | $1.07M | $1.05M | $1.08M | $948,000 | $999,000 | $890,000 | $956,000 | $988,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.